Hosted by Katerina Roznik · 🇺🇸 US · EN · 43 episodes
Established thought leaders with verified media credentials.
Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.For more content, please subscribe to biotechblueprint.substack.com.
Katerina Roznik hosts Biotech Blueprint, a technology show with 43 episodes published.
Subscribe to Biotech Blueprint for free at biotechblueprint.com In the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands in 2026. We work thro
Subscribe to Biotech Blueprint for free at biotechblueprint.com.
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026). Follow Biotech Blueprint at biotechblueprint.com .
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026). Subscribe to Biotech Blueprint at biotechblueprint.com .
This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com . KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall survival win, and Co
Subscribe to This Week in Biotech for free at biotechblueprint.com .
I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at boosting response rates, an
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025). Subscribe to Biotech Blueprint for free at biotechblueprin
Subscribe to Biotech Blueprint at biotechblueprint.com
Subscribe to Biotech Blueprint for free at biotechblueprint.com . A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins.
Subscribe to Biotech Blueprint at biotechblueprint.com In today's episode:How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
Subscribe to Biotech Blueprint for free at biotechblueprint.com . Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher bid, leaving Pfizer tw
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com .
Subscribe to Biotech Blueprint for FREE at biotechblueprint.com .
Subscribe to Biotech Blueprint for free at biotechblueprint.com . About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how
Subscribe at biotechblueprint.com .
Read the full edition or subscribe to Biotech Blueprint here https://www.biotechblueprint.com/p/pharma-tariffs-on-ice-fda-limits?r=474vk1
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com/embed
Welcome to Biotech Blueprint. If you want to subscribe to a free weekly biotech/pharma newsletter, you can do so here: https://www.biotechblueprint.com/embed In this special episode, I teamed up again with Hartaj from th
Subscribe to Biotech Blueprint, your free biotech & pharma newsletter released every Friday at biotechblueprint.com
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Biotech Blueprint, visit https://biotechblueprint.substack.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent technology coverage.
Biotech Blueprint is hosted by Katerina Roznik. The show is categorised under technology and has published 43 episodes.
Biotech Blueprint has published 43 episodes.
Biotech Blueprint regularly covers technology. It sits in the technology category.
Biotech Blueprint is accessible for guests with genuine technology expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Biotech Blueprint hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Biotech Blueprint average 17 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Biotech Blueprint's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 10 days ago.
